Literature DB >> 8902324

Substance use disorder exacerbates brain electrophysiological abnormalities in a psychiatrically-ill population.

E R Braverman1, K Blum.   

Abstract

OBJECTIVE: To assess by brain electrical activity mapping whether cocaine and alcohol abuse and dependence would exacerbate electro-physiological abnormalities in a psychiatrically-ill population. DESIGN, SETTING, AND PARTICIPANTS: Utilizing a brain mapping system, we assessed EEG, Spectral Analysis (Quantitative EEG[QEEG]). Evoked Potentials (Auditory and Visual), and P300 (cognitive evoked potential), in a total of 111 probands divided into three groups: controls (N = 16), psychiatrically-ill without comorbid substance use disorder (N = 34), and psychiatrically-ill with comorbid substance use disorder (cocaine and alcohol abuse and dependence) (N = 61), at an outpatient neuropsychiatric clinic. With regard to demographic data, the group participating in this study did not differ significantly. A comparison was made among the groups to assist in differentiating the effects of substance use disorder compared to psychiatric disease on brain electrical activity. MAIN OUTCOME MEASURES: An assessment of electrophysiological abnormalities and their brain location in psychiatric and substance use disorder patients was done with a brain electrical activity mapping test. MAIN
RESULTS: Among the non-substance use disorder, psychiatrically-ill (PI) and substance use disorder, psychiatrically-ill (PI/SD) groups, significantly different brain map abnormalities were observed relative to an assessed normal population MANOVA (P = .017). Moreover, with regard to Spectral Analysis, ANOVA was significant at a P = .038, and we found a weighted linear trend of increased abnormal total spectral analysis (P = .0113), whereby substance use was significantly worse than controls. Moreover among the PI and PI/SD groups, significantly greater total evoked potential (EP) brain trap abnormalities were observed when compared with a characterized normal population (P = .0023) with increasing abnormalities as a function of substance use disorder as measured by a weighted linear trend (P = .0022). In order to determine the site of the EPS abnormalities, we evaluated these abnormalities by location. In this regard, we found all temporal abnormalities (AVBITA, see Table 2) among the PI and PI/SD groups to be significantly greater relative to an assessed normal population (P = .0026). Furthermore, we observed a linear trend of increased temporal abnormalities with increasing substance use disorder (P < .0008). In terms of bitemporal abnormalities (AVBIT) among the PI and PI/SD groups, we also found significantly more bitemporal lobe abnormalities in the PI/SD group compared to our control population (P = .009). Additionally, a weighted linear trend of increased abnormal bitemporal lobe abnormalities was observed with increasing substance use disorder (P = .0022). In the frontal lobe similar findings were observed. With AVBIFA the ANOVA was P < .011, with a weighted linear trend of P < .005 and the PI/SD group were significantly more abnormal than PI or CS on a Duncan Range test. It is noteworthy that in a selected group of depressed (Major Depressive Disorder Recurrent, 296.3) patients, we found profound abnormalities in the various brain map parameters tested. MANOVA and Univariate ANOVA's revealed significantly greater abnormalities in the PI and PI/SD groups compared to assessed controls. A MANOVA for total brain abnormalities was significant at P = .043 and univariate ANOVA's for composite measurements of TSA (P = .017), EPS (P = .0002), AVBITA (P = .000015), and AVBIT (P < .00002) are also significant. With regard to EPS and AVBITA a weighted linear trend was observed where there were increasing abnormalities with increasing substance use disorder, P = .0001 and P = .000003, respectively. Most importantly we found that in addition to increased abnormalities with increasing substance use disorder the PI/SD group had significantly more abnormalities compared to the PI group with regard to both the TSA (P < .05) and AVBIT (P < .05) composite parameters as meas

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8902324     DOI: 10.1177/1550059496027s0402

Source DB:  PubMed          Journal:  Clin Electroencephalogr        ISSN: 0009-9155


  10 in total

1.  Hypothesizing That Neuropharmacological and Neuroimaging Studies of Glutaminergic-Dopaminergic Optimization Complex (KB220Z) Are Associated With "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).

Authors:  Kenneth Blum; Marcelo Febo; Lyle Fried; Mona Li; Kristina Dushaj; Eric R Braverman; Thomas McLaughlin; Bruce Steinberg; Rajendra D Badgaiyan
Journal:  Subst Use Misuse       Date:  2016-12-29       Impact factor: 2.164

2.  Proposing a "Brain Health Checkup (BHC)" as a Global Potential "Standard of Care" to Overcome Reward Dysregulation in Primary Care Medicine: Coupling Genetic Risk Testing and Induction of "Dopamine Homeostasis".

Authors:  Eric R Braverman; Catherine A Dennen; Mark S Gold; Abdalla Bowirrat; Ashim Gupta; David Baron; A Kenison Roy; David E Smith; Jean Lud Cadet; Kenneth Blum
Journal:  Int J Environ Res Public Health       Date:  2022-04-30       Impact factor: 4.614

3.  Plasma growth hormones, P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting: evidence supported by structural equation modeling (SEM) parameter estimates.

Authors:  Eric R Braverman; Thomas J H Chen; Thomas J Prihoda; William Sonntag; Brian Meshkin; B William Downs; Julie F Mengucci; Seth H Blum; Alison Notaro; Vanessa Arcuri; Michael Varshavskiy; Kenneth Blum
Journal:  Age (Dordr)       Date:  2007-05-12

4.  Neurogenetic Impairments of Brain Reward Circuitry Links to Reward Deficiency Syndrome (RDS): Potential Nutrigenomic Induced Dopaminergic Activation.

Authors:  K Blum; M Oscar-Berman; J Giordano; Bw Downs; T Simpatico; D Han; John Femino
Journal:  J Genet Syndr Gene Ther       Date:  2012-10-17

5.  Diagnosis and Healing In Veterans Suspected of Suffering from Post-Traumatic Stress Disorder (PTSD) Using Reward Gene Testing and Reward Circuitry Natural Dopaminergic Activation.

Authors:  Kenneth Blum; John Giordano; Marlene Oscar-Berman; Abdalla Bowirrat; Thomas Simpatico; Debmalya Barh
Journal:  J Genet Syndr Gene Ther       Date:  2012-05-31

6.  Should We Embrace the Incorporation of Genetically Guided "Dopamine Homeostasis" in the Treatment of Reward Deficiency Syndrome (RSD) as a Frontline Therapeutic Modality?

Authors:  Kenneth Blum; Ali Raza; Tiffany Schultz; Rehan Jalali; Richard Green; Raymond Brewer; Panyotis K Thanos; Thomas McLaughlin; David Baron; Abdalla Bowirrat; Igor Elman; B William Downs; Debasis Bagchi; Rajendra D Badgaiyan
Journal:  Acta Sci Neurol       Date:  2021-02-02

7.  Hypothesizing that a Pro-Dopaminergic Regulator (KB220z Liquid Variant) can Induce "Dopamine Homeostasis" and Provide Adjunctive Detoxification Benefits in Opiate/Opioid Dependence.

Authors:  Kenneth Blum; Debra Whitney; Lye Fried; Marcelo Febo; Roger L Waite; Eric R Braverman; Kristina Dushaj; Mona Li; John Giordano; Zsolt Demetrovics; Rajendra D Badgaiyan
Journal:  Clin Med Rev Case Rep       Date:  2016-08-16

8.  Improvement of long-term memory access with a pro-dopamine regulator in an elderly male: Are we targeting dopamine tone?

Authors:  Thomas McLaughlin; David Han; James Nicholson; Bruce Steinberg; Kenneth Blum; Marcelo Febo; Eric Braverman; Mona Li; Lyle Fried; Rajendra Badgaiyan
Journal:  J Syst Integr Neurosci       Date:  2017-06-17

9.  The Molecular Neurobiology of Twelve Steps Program & Fellowship: Connecting the Dots for Recovery.

Authors:  Kenneth Blum; Benjamin Thompson; Zsolt Demotrovics; John Femino; John Giordano; Marlene Oscar-Berman; Scott Teitelbaum; David E Smith; A Kennison Roy; Gozde Agan; James Fratantonio; Rajendra D Badgaiyan; Mark S Gold
Journal:  J Reward Defic Syndr       Date:  2015

10.  Neurobiology of KB220Z-Glutaminergic-Dopaminergic Optimization Complex [GDOC] as a Liquid Nano: Clinical Activation of Brain in a Highly Functional Clinician Improving Focus, Motivation and Overall Sensory Input Following Chronic Intake.

Authors:  Lucien L Duquette; Frank Mattiace; Kenneth Blum; Roger L Waite; Teresa Boland; Thomas McLaughlin; Kristina Dushaj; Marcelo Febo; Rajendra D Badgaiyan
Journal:  Clin Med Rev Case Rep       Date:  2016-05-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.